Novel Vaccines
Undisclosed
Key Facts
About MSD
MSD Ireland is a cornerstone of Merck & Co.'s global network, serving as a premier European hub for R&D and manufacturing across biologics, small molecules, and vaccines. With over 3,600 employees across eight strategic sites and approximately $3.5 billion invested in the last 3.5 years, it is a top-tier contributor to Ireland's life sciences economy. The subsidiary's strategy is deeply integrated with the parent company's focus on scientific excellence, pipeline commercialization, and expanding global access to critical therapies.
View full company profileTherapeutic Areas
Other Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| Preclinical ISAC 1 | Bolt Biotherapeutics | Preclinical |
| Preclinical ISAC 2 | Bolt Biotherapeutics | Preclinical |
| ART12.11 | Artelo Biosciences | Preclinical |
| SLS-009 | Seelos Therapeutics | Discovery |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |
| Internal sdAb Discovery Program | NanoTag Biotechnologies | Discovery |
| Amgen Collaboration Program | Xeris Biopharma | Pre-clinical |
| NB-701 | Nerai Biosciences | Discovery |
| Undisclosed Therapeutic Program(s) | Bright Cell | Clinical Trial (Phase unspecified) |
| Biosimilars Pipeline | Intelligent Therapeutics | Pre-clinical/Development |
| Proprietary Therapeutic Pipeline | Excelsior Sciences | Discovery |
| Therapeutic Programs | Agathos Biologics | Pre-clinical |